- Pharmaceuticals
- Endocarditis Treatment Market
Endocarditis Treatment Market Size, Share, and Growth Forecast 2026 - 2033
Endocarditis Treatment Market by Treatment Type (Antibiotic Therapy, Surgical Intervention), Drug Class (Glycopeptides, Lipopeptides), End-User (Hospitals, Outpatient Infusion and Ambulatory Care), and Regional Analysis, 2026 - 2033
Endocarditis Treatment Market Size and Trends Analysis
The global endocarditis treatment market size is likely to be valued at US$2.8 billion in 2026 and is estimated to reach US$4.2 billion by 2033, growing at a CAGR of 6% during the forecast period from 2026 to 2033, driven by a rising disease burden, more injection drug use-related cases, and surging use of valve surgery and catheter-based care. New oral and outpatient treatment pathways are further changing how hospitals manage patients.
Key Industry Highlights:
- Leading Treatment Type: Antibiotic therapy, about 71.3% share in 2026, as every case needs prolonged antimicrobial treatment, usually four to six weeks of intravenous therapy.
- Dominant End-User: Hospitals, around 78.6% share in 2026, as diagnosis, imaging, surgery, and intensive care are delivered by multi-disciplinary endocarditis teams.
- Leading Region: North America, with about a 38.2% share in 2026, due to a high caseload, rising injection drug use-related disease, and strong access to advanced care.
- Fast-growing Region: Asia Pacific, due to aging populations, rheumatic heart disease, and the highest national endocarditis burdens in India and Thailand.
- Latest Analysis: In April 2026, a nationwide Danish NIDUS registry analysis provided new treatment and outcome data for cardiac implantable electronic device (CIED)-related endocarditis. Among 340 patients with isolated CIED-related infective endocarditis, device removal was performed in 78.2% of cases. The study highlighted the distinct clinical profile of device-associated endocarditis and the importance of device extraction as part of treatment, particularly as the use of implanted cardiovascular devices continues to expand.

DRO Analysis
Driver - Rising Disease Burden and Aging Populations to Propel Treatment Demand
Endocarditis cases keep rising. Global Burden of Disease data show 1.09 million cases in 2019. The global age-standardized incidence rate rose from 9.35 per 100,000 in 1990 to 12.61 per 100,000 in 2021. It was highest in high-income regions, at 15.77 per 100,000. In the U.S., there are 40,000 to 50,000 new cases a year, and hospital stays can cost more than US$120,000.
The disease is severe. Mortality can reach 30% within the first year after diagnosis. In England, about half of patients need early cardiac surgery. Researchers link the growing burden to population growth and aging, since rates rise steadily with age. A larger elderly population with valve disease, prosthetic valves, and cardiac devices will keep demand for treatment high.
Injection Drug Use-related Cases to Bolster Demand Worldwide
Injection drug use has changed the patient profile. Endocarditis once mainly affected older adults and immunocompromised people. It now affects young people who inject drugs. A national U.S. sample showed that endocarditis hospitalizations rose 38% from 2000 to 2013, while injection drug use-related cases rose 238%. Later analyses show up to a 12-fold rise between 2007 and 2017.
These cases are complex. Staphylococcus aureus is involved in 43% to 95% of first episodes. A growing share involves resistant organisms. Many patients need long antibiotic courses, surgery, and addiction care together. Hospitals hence need more beds, imaging, infusion services, and specialist teams, which supports spending on antibiotics and procedures.
Restraint - Short Courses and Limited Trial Evidence May Slow Growth
Treatment is moving toward less drug use per patient. POET-II found that a response-tailored strategy cut antibiotic duration by two weeks, or about one-third. Investigators estimate that around half of left-sided patients could be eligible. The earlier POET trial also supported oral step-down therapy after at least 10 days of intravenous treatment. Shorter courses and oral switches can lower intravenous drug volumes.
Evidence gaps remain for newer options. The DOTS trial found that dalbavancin was not superior to standard therapy in complicated S. aureus bacteremia. It excluded left-sided endocarditis. Surgery is also underused. It is performed in only 5% to 40% of eligible patients, and tricuspid valve surgery carries an operative mortality of 6% to 10%. Resistant organisms add further pressure.
Opportunity - Oral and Outpatient Therapy to Open New Care Pathways
Guidelines now support new pathways. The 2023 European Society of Cardiology (ESC) guidelines added 34 new recommendations and included outpatient parenteral and oral antibiotic options based on POET. The POET trial randomized 199 patients to continued intravenous therapy and 201 to oral step-down. In 2026, the American Heart Association updated its scientific statement and now treats partial oral therapy as an option for carefully selected patients.
Long-acting drugs may also gain a role. Dalbavancin has a terminal half-life of 14 days, and the DOTS trial gave it on days 1 and 8. Case series have reported high clinical success in endocarditis. Suppliers of oral agents, long-acting antibiotics, infusion pumps, and outpatient infusion services can benefit as hospitals try to shorten stays and free beds.
Percutaneous Debulking and Endocarditis Teams to Expand Procedural Care
Catheter-based care fills a surgical gap. Large-bore transcatheter aspiration systems have received FDA clearance for debulking right-sided intracardiac masses. The CLEAR-IE registry followed 256 patients with right-sided endocarditis from 19 U.S. centers between 2014 and 2024. The composite of in-hospital death, new pulmonary embolism, or emergency surgery occurred in 18%. Randomized data are still awaited.
Team-based care is also growing. The 2026 American Heart Association statement places the endocarditis team at the center of care and adopts the 2023 Duke-ISCVID diagnostic criteria. The ESC added new recommendations on computed tomography, nuclear imaging, and magnetic resonance. Devices, imaging, and surgical suppliers can all benefit from more structured pathways.
Category-wise Analysis
Treatment Type Insights
Antibiotic therapy is predicted to lead with a share of about 71.3% in 2026, as it is needed in every case. Standard care usually requires four to six weeks of intravenous therapy. Treatment depends on the organism. In the DOTS trial, standard therapy used cefazolin for methicillin-sensitive S. aureus and vancomycin or daptomycin for MRSA. Rising case numbers keep volumes high.
Percutaneous and device-based intervention is estimated to be the fastest-growing segment over the forecast period, as many patients are poor surgical candidates. Aspiration systems can debulk vegetations in right-sided disease. The CLEAR-IE registry reported procedural data from 256 patients. An AHA science advisory has also reviewed the technique. Growing evidence may lift adoption.
End-User Insights
Hospitals are anticipated to dominate with a share of around 78.6% in 2026, as endocarditis needs echocardiography, advanced imaging, intravenous therapy, and cardiac surgery. Echocardiography remains the first-line test. Hospitals also host endocarditis teams, which bring together cardiology, infectious disease, and surgery. Complex cases such as device-related disease need tertiary care.
Outpatient infusion and ambulatory care are expected to remain in the second position in 2026, as stable patients move to oral or outpatient therapy. ESC guidelines include outpatient parenteral and oral options. In DOTS, dalbavancin was given on two days to complete therapy. These approaches shorten stays and reduce catheter-related risks.
Regional Insights
North America Endocarditis Treatment Market Trends
North America is predicted to dominate with a global share of approximately 38.2% in 2026, supported by a high incidence of infective endocarditis, substantial hospital-based treatment, advanced cardiac surgery infrastructure, and broad access to new antimicrobial and interventional technologies. The U.S. has experienced a significant increase in endocarditis hospitalizations, with injection drug use becoming an increasingly important contributor to the patient pool. Treatment in the region is also becoming more diversified. Conventional intravenous antibiotics remain the mainstay, but selected stable patients are now being considered for outpatient parenteral or oral step-down therapy.
U.S. Endocarditis Treatment Market Trends
A share of nearly 76.1% is expected to be held by the U.S. in 2026 in North America, reflecting its large healthcare expenditure, high hospitalization burden, extensive cardiac surgery network, and comparatively rapid adoption of advanced medical technologies. The country's endocarditis burden has risen substantially over the past two decades. A GBD-based analysis of 19 high-income countries identified a particularly steep recent increase in age-standardized incidence in the U.S., alongside the U.K. and Germany. The U.S. market is additionally becoming an important launch and adoption market for new treatment approaches. Long-acting antibiotics, oral step-down regimens, and large-bore mechanical aspiration technologies are being evaluated or adopted for appropriately selected patients. This is relevant for right-sided endocarditis associated with injection drug use, where avoiding or delaying open surgery can be clinically valuable.
Asia Pacific Endocarditis Treatment Market Trends
Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 27.7%, due to a large and aging population, persistent rheumatic heart disease in several countries, increasing cardiovascular interventions, and gradual expansion of cardiac diagnostic and surgical infrastructure. The epidemiology is highly diverse across the region. GBD 2021 data show that Thailand had the highest age-standardized incidence rate of infective endocarditis globally in 2021, at 33.55 cases per 100,000 population, while several other Asian countries also recorded substantial disease burdens. The region presents an important opportunity for antibiotic treatment because access to sophisticated surgery and interventional endocarditis care remains uneven between countries and between urban and rural areas.
China Endocarditis Treatment Market Trends
China will likely lead in Asia Pacific in 2026 with a share of about 38.9%, owing to its population size, rapidly aging demographic, expanding cardiovascular-care infrastructure, and increasing detection of infective endocarditis. A 2025 BMJ Open study using GBD 2021 data found that the number of incident endocarditis cases in China increased from 133,846 in 1990 to 264,282 in 2021. The age-standardized incidence rate increased from 12.34 to 14.38 per 100,000 over the same period. The country’s age-standardized DALY rate fell substantially, reaching 3.46 per 100,000 in 2021, the lowest among the G20 countries examined in the study. This combination of rising case numbers and falling age-standardized disease burden suggests that demographic expansion and population aging are important drivers of absolute treatment demand even as outcomes and disease burden relative to population improve.
India Endocarditis Treatment Market Trends
In 2026, India is projected to account for a share of just about 17.2% in Asia Pacific, supported by rheumatic heart disease, a large population, increasing cardiovascular disease awareness, and a growing number of patients reaching tertiary cardiac centers. GBD analyses demonstrate substantial geographical variation in endocarditis burden, while the broad global evidence shows that incidence tends to be higher in countries and populations with greater cardiovascular and healthcare exposure.
Europe Endocarditis Treatment Market Trends
Europe will likely witness steady growth over the forecast period with a share of roughly 17.6% in 2026 globally, backed by sophisticated cardiovascular infrastructure, established cardiac-surgery networks, strong infectious-disease expertise, and a highly developed clinical-trial environment. Europe is also at the forefront of changes in how endocarditis is managed. The 2023 ESC Guidelines introduced updated recommendations covering diagnosis, imaging, antimicrobial treatment, surgery, outpatient parenteral therapy, oral step-down treatment, prosthetic-valve endocarditis, and infections involving cardiac implantable electronic devices.
Germany Endocarditis Treatment Market Trends
Germany is predicted to register a substantial share of approximately 27.3% in 2026 in Europe, owing to its large population, advanced hospital infrastructure, high cardiac-surgery capacity, and strong position in cardiovascular research. GBD-based research identified Germany among the countries experiencing a steep recent increase in age-standardized endocarditis incidence. Germany also has a particularly strong role in shaping European endocarditis treatment because of its involvement in major clinical studies and guideline development. The country has been closely associated with research into oral and shortened antibiotic strategies, including the POET program.
U.K. Endocarditis Treatment Market Trends
In Europe, a share of nearly 15.6% is predicted to be held by the U.K. in 2026, supported by increasing incidence, a centralized healthcare system, established cardiac-surgery services, and substantial clinical research activity. The market is further characterized by a strong focus on antimicrobial stewardship and prevention. NICE's endocarditis guidance has historically stated that antibiotic prophylaxis before dental procedures is not routinely recommended, while its 2024 surveillance work sought to clarify implementation for patients at particularly high risk.

Competitive Landscape
The global endocarditis treatment market is moderately fragmented and highly therapy-driven, with competition spread across established antibiotics, newer anti-MRSA agents, long-acting lipoglycopeptides, and emerging catheter-based vegetation-removal technologies. Unlike multiple conventional pharmaceutical markets, competition is not determined solely by the availability of branded drugs because treatment depends heavily on the infecting organism, valve type, disease severity, antimicrobial susceptibility, and whether surgery or device extraction is required.
The 2026 American Heart Association statement also emphasizes multidisciplinary Endocarditis Teams and individualized treatment, reinforcing the importance of clinical capability alongside the drug itself. Established antibiotics continue to form the competitive foundation. Generic and established agents such as vancomycin, daptomycin, nafcillin/oxacillin, cefazolin, ceftriaxone, gentamicin, and ampicillin remain important. This is because clinicians select therapy according to pathogen susceptibility and whether the infection involves a native valve, prosthetic valve, or cardiac device.
Key Industry Developments:
- In September 2026, the American Heart Association released an updated scientific statement on infective endocarditis management, highlighting the shift toward individualized treatment through multidisciplinary Endocarditis Teams, earlier procedural intervention, alternative antimicrobial strategies, and newer diagnostic technologies. The statement noted that advances in molecular pathogen detection, imaging, radiopharmaceutical techniques, and artificial intelligence are increasingly influencing diagnosis and monitoring, potentially enabling more targeted treatment decisions.
- In September 2026, the REASSESS-IE study showed that follow-up imaging before stopping antibiotics can alter treatment decisions in a subset of infective endocarditis patients with embolic complications. Among 554 patients receiving antibiotic therapy, follow-up imaging led to treatment modification in 5.7% of those imaged, with changes occurring particularly among patients with S. aureus endocarditis complicated by abscesses. The findings support a more individualized approach to determining when antimicrobial therapy can safely be discontinued.
- In April 2026, the Kirby Institute initiated the OSCAR Phase II study of oritavancin for serious cardiac infections, including infective endocarditis and cardiovascular implantable electronic-device infections. The multicenter Australian trial is evaluating fixed-dose versus therapeutic-drug-monitoring-guided dosing of the long-acting lipoglycopeptide in gram-positive cardiac infections. The study is designed to generate pharmacokinetic, safety, and preliminary efficacy data that could support alternatives to prolonged inpatient IV antibiotic treatment.
Companies Covered in Endocarditis Treatment Market
- Pfizer Inc.
- Merck & Co., Inc.
- AbbVie Inc.
- Baxter International Inc.
- Fresenius Kabi AG
- Xellia Pharmaceuticals ApS
- Melinta Therapeutics, LLC
- Cumberland Pharmaceuticals Inc.
- Edwards Lifesciences Corporation
- Medtronic plc
- Abbott Laboratories
- AngioDynamics, Inc.
- Others
Frequently Asked Questions
The global endocarditis treatment market is projected to be valued at US$2.8 billion in 2026.
The endocarditis treatment market is expected to reach US$4.2 billion by 2033.
Key market trends include oral step-down therapy, tailored antibiotic duration, percutaneous debulking, and multidisciplinary endocarditis teams.
Antibiotic therapy is expected to be the leading treatment type with a share of around 71.3% in 2026, as every case needs prolonged antimicrobial treatment.
The endocarditis treatment market is expected to grow at a CAGR of 6% from 2026 to 2033.
Pfizer Inc., Merck & Co., Inc., and AbbVie Inc. are a few key market players.




